Roche Licenses Rona’s ALK7-Targeting RNAi Candidate For Obesity And Metabolic Diseases, With Rona Eligible For Up To $1.06B In Milestones Plus Royalties
Share
Why It Matters
Roche bought the rights to a new medicine from Rona that fights obesity. This deal shows Roche believes in the medicine's potential and may pay Rona lots of money if it works well.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.